In contrast, sorafenib, as an oral multikinase inhibitor, blocks TGF-β signaling, decreasing the expression of collagen and pro-fibrotic genes, resulting in a reduction of tumor-stroma stiffness and a weakening of inter-tumor stress. This evidence concerns the gene TGFB1 and neoplasm.